TERN-601, a once-daily oral small-molecule GLP-1 receptor agonist, produced statistically significant, dose-dependent weight loss over 28 days in Phase 1, with all doses outperforming placebo. In the 12-week Phase 2 trial, doses ≥500 mg delivered meaningfully greater mean percentage weight loss versus placebo, alongside classic GLP-1 pharmacodynamic signatures — reduced appetite and delayed gastric emptying. Gastrointestinal adverse events were class-consistent and dose-related. Critically, three Phase 2 participants developed transaminase elevations signaling potential drug-induced liver injury (DILI), prompting full clinical discontinuation.
The oral GLP-1 space is fiercely competitive: semaglutide (Rybelsus) already holds approval, and multiple small-molecule candidates — including Eli Lilly's orforglipron and Structure Therapeutics' GSBR-1290 — are in late-stage trials. TERN-601's DILI signal is a sobering reminder that small-molecule GLP-1 agonists, which differ structurally from peptide-based injectables, carry hepatotoxicity risks not seen with semaglutide or tirzepatide. The liver finding in just three participants was sufficient to kill the program, reflecting regulators' and sponsors' low tolerance for idiosyncratic hepatotoxicity after high-profile DILI withdrawals in other drug classes. For the broader field, this data point reinforces that oral bioavailability engineering in this target class must be scrutinized for off-target liver metabolism. Efficacy was modest — not paradigm-shifting — making the safety trade-off clearly unacceptable. An important cautionary dataset as the oral obesity pharmacology pipeline matures.
